Clinical Trial

Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Breakthrough chemotherapy-induced vomiting (CIV) is defined as CIV occurring after adequate antiemetic prophylaxis. Olanzapine is recommended for the treatment of breakthrough CIV in children, without adequate evidence. We conducted an open-label, single-center, phase 3 randomized controlled trial comparing the safety and efficacy of olanzapine and metoclopramide for treating breakthrough CIV.
Trial Details
NCT Number NCT07035821
Lead Sponsor Shanghai Children's Medical Center
Conditions Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer
Enrollment 100 participants
Start Date 2025-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-25